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Abstract Recent advances in basic cardiovascular
research as well as their translation into the clinical
situation were the focus at the last ‘‘New Frontiers in
Cardiovascular Research meeting’’. Major topics included
the characterization of new targets and procedures in
cardioprotection, deciphering new players and inflamma-
tory mechanisms in ischemic heart disease as well as
uncovering microRNAs and other biomarkers as versatile
and possibly causal factors in cardiovascular pathogenesis.
Although a number of pathological situations such as
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ischemia–reperfusion injury or atherosclerosis can be
simulated and manipulated in diverse animal models, also
to challenge new drugs for intervention, patient studies are
the ultimate litmus test to obtain unequivocal information
about the validity of biomedical concepts and their appli-
cation in the clinics. Thus, the open and bidirectional
exchange between bench and bedside is crucial to advance
the field of ischemic heart disease with a particular
emphasis of understanding long-lasting approaches in
cardioprotection.
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Introduction
Ischemic heart disease (IHD) is the leading cause of death
and disability worldwide [104]. Thus, new treatment
strategies are required to protect the heart from the detri-
mental effects of acute ischemia/reperfusion injury (IRI) so
as to reduce myocardial injury, to preserve left ventricular
systolic function, and to prevent the onset of heart failure
[40]. During the 2nd International Symposium on ‘‘New
Frontiers in Cardiovascular Research’’ (Huatulco-Oaxaca,
Mexico), basic researchers and clinicians discussed new
biomedical developments as well as novel targets and
respective interventional strategies in the areas of heart
failure, inflammatory mechanisms, and cardioprotection. In
essence, the meeting covered heterogenous and unrelated
intra- as well as extracellular molecular targets such as
cytokines, ion channels, extracellular nucleic acids, or
mitochondrial factors, which are all linked to the devel-
opment or prevention of IHD, which not only reflect the
complexity of the biological system but also indicate the
variety of possible interventional approaches that can be
helpful or even lifesaving as a cardioprotective strategy.
The challenges of translating cardioprotection
into the clinical setting
Derek Yellon (UK) opened the meeting by providing an
expert overview of cardioprotection from bench-to-bedside
with focus given to new therapeutic targets for cardiopro-
tection and the challenges facing the translation of new
cardioprotective therapies from the laboratory to the clin-
ical arena; a topic which has been extensively discussed in
recent literature, and which has been attributed to a number
of factors including the use of inappropriate animal models
and poor clinical trial design (reviewed in [27, 29, 33, 52]).
In particular, the influence of co-morbidities (e.g., diabetes,
hypertension, and hyperlipidemia) and concomitant medi-
cation (nitrates, volatile anesthetics, and propofol) on car-
dioprotection is important factors to take into
consideration, especially given the wealth of preclinical
data suggesting that these factors confound cardioprotec-
tion [20].
The heart can be protected from acute IRI, both exper-
imentally and in the clinical setting, by subjecting it to brief
episodes of ischemia and reperfusion, a phenomenon ter-
med ‘‘ischemic preconditioning’’ [72]. However, this
manipulation requires an invasive strategy applied directly
to the heart and also necessitates that the intervention is
applied prior to the index ischemic episode, which of
course is not possible in patients presenting with an acute
myocardial infarction (MI). Here, the intervention by
remote ischemic conditioning (RIC), a noninvasive, low-
cost, easily administered cardioprotective procedure, can
be applied after the onset of myocardial ischemia and,
therefore, has therapeutic potential for patients with ST-
segment elevation myocardial infarction (STEMI), treating
by primary percutaneous coronary intervention (PPCI) [31,
37, 78, 93] or thrombolysis [107]. RIC can be delivered by
inflating a standard blood pressure cuff placed on the upper
arm or thigh, to induce brief cycles of ischemia and
reperfusion to the arm or leg. Whether RIC has the
potential to improve short-term clinical outcomes [71, 94,
101] and to prevent long-term major adverse cardiac events
in this patient group is currently being investigated by Hans
Botker and Derek Hausenloy in the CONDI2/ERIC-PPCI
trial, a 4300 STEMI patient international (Denmark, UK,
and Spain), multicentre randomized controlled clinical trial
by investigating whether RIC can reduce the rates of car-
diac death and hospitalization for heart failure at
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12 months (ClinicalTrials.gov Identifiers: NCT01857414
and NCT02342522). Interestingly, Botker’s group has
found that certain co-morbidities (age, diabetes, hyperten-
sion, high body mass index, hyperlipidemia, and left ven-
tricular hypertrophy), and concomitant medications (b-
blocker, ACE-inhibitor, calcium antagonists, and statins)
did not appear to affect the cardioprotective efficacy of RIC
in reperfused STEMI patients. Although there is a wealth
of preclinical data indicating that co-morbidities and con-
comitant medication can confound endogenous cardiopro-
tection much of the evidence is restricted to ischemic
preconditioning and postconditioning as opposed to remote
ischemic conditioning [20].
The results of the recently published ERICCA [28] and
RIPHeart [67] multicentre clinical trials have raised the issue
of whether concomitant medication can interfere with the
cardioprotective effects of RIC in patients undergoing car-
diac surgery. In these large clinical outcome studies, RIC
using transient arm ischemia/reperfusion was found to have
no effect in terms of reducing perioperative myocardial
injury or improving short-term or long-term major adverse
cardiovascular events. It has been suggested that the use of
propofol anesthesia may have, in part, attenuated the car-
dioprotective effects of RIC in the setting of cardiac surgery
[48, 49], although the mechanism for this interaction remains
unclear and needs to be investigated [38]. The role of
propofol in cardioprotection is quite complex and, at times,
the data appear inconsistent. A number of experimental
studies [54, 59] and even one clinical study in cardiac surgery
[87] have found propofol to protect the myocardium against
acute ischemia/reperfusion injury through an antioxidant
effect and inhibition of MPTP opening [42]. Moreover, there
is no clear relationship between propofol use and the car-
dioprotective efficacy of RIPC, with several clinical studies
demonstrating RIPC cardioprotection despite the presence
of propofol, and others finding no benefit with RIPC, even in
the absence of propofol.
Mitochondria as targets for cardioprotection
Mitochondrial dysfunction lies at the heart of a number of
cardiovascular diseases including acute IRI, and treatments
aimed at preserving mitochondrial function represent an
important cardioprotective strategy for limiting MI size and
preserving cardiac function [36]. Glycogen synthase
kinase-3b (GSK-3b), a constitutively active multifunc-
tional kinase, is an important downstream target of a
number of pro-survival signaling pathways, recruited by
cardioprotective strategies, such as ischemic conditioning,
as it contributes to IRI by increasing the susceptibility to
mitochondrial permeability transition pore (MPTP)
opening [100]. The interplay between GSK-3b and mito-
chondria in the context of acute myocardial IRI was
addressed by Tetsuji Miura (Japan) by showing that the
mitochondrial translocation of GSK-3b by oxidant stress
appears to be mediated by its kinase-dependent interaction
with the voltage-dependent anion channel 2 and that
translocated GSK-3b interacted with complex III of the
electron transport chain, leading to increased cytotoxic
reactive oxygen species (ROS) production [99, 100].
Although the therapeutic inhibition of the mitochondrial
translocation of GSK-3b may provide a promising
approach to cardioprotection without disturbing the phys-
iological functions of GSK-3b, certain co-morbidities such
as diabetes, hypertension, and chronic renal failure can
disrupt cytoprotective signaling pathways of GSK-3b at
different sites, and this may contribute, in part, to the
heightened harmful effects of acute myocardial IRI under
these medical conditions.
The phenomenon of ‘‘mitochondrial dynamics’’ was
introduced by Derek Hausenloy (UK and Singapore) as a
novel target for cardioprotection—this refers to the ability
of mitochondria to move and change shape by undergoing
fission and fusion to generate fragmented and elongated
mitochondria, respectively [26, 74, 75]. These processes
are required to maintain healthy mitochondria and normal
cell function, and their genetic or pharmacological inhibi-
tion offer a potential cardioprotective strategy [76]. In
particular, the manipulation of mitochondrial fusion pro-
teins such as mitofusin 2 (Mfn2) in the adult heart pro-
duced unexpected results in terms of cardioprotection [17].
This fusion protein has been shown to act as a tether
between the sarcoplasmic reticulum (SR) and mitochondria
[16] and thereby facilitates calcium signaling between
these two organelles as a critical step in the coupling of
mitochondrial energy production with the energy require-
ments of the contractile system. Cardiac-specific deletion
of the mitochondrial fusion proteins Mfn1 and Mfn2 in the
adult murine heart resulted in reduced infarct size when
compared to wild-type littermates. This cardioprotective
effect appeared to be mediated by the dissociation of the
SR from mitochondria, thereby disrupting calcium signal-
ing between both organelles and decreasing mitochondrial
calcium overload, attenuating oxidative stress and
decreasing MPTP opening. Recent data indicate that the
mitochondrial fusion and fission proteins appear to provide
therapeutic targets in heart failure, pulmonary hyperten-
sion, or cardiomyocyte stem cell differentiation as well [26,
75, 78]. Yet, based upon their pleiotropic functions,
manipulation of these mitochondrial fusion and fission
proteins needs to be precisely defined in each acute setting
in order to prevent detrimental off-target effects such as
cardiomyopathy.
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The impact of advanced age on mitochondrial dys-
function, which occurs in the context of acute myocardial
IRI, was discussed by Marisol Ruiz-Meana (Spain). Pre-
clinical data have suggested that mitochondria play a
causative role in the increased susceptibility of the senes-
cent myocardium to ischemic damage. The existence of an
age-dependent disruption of the molecular communication
between SR and mitochondria appears to have conse-
quences on calcium handling and bioenergetics in response
to acute myocardial IRI [22]. Moreover, oxidation of
mitochondrial ATP synthase aggravated mitochondrial
membrane permeabilization and cell death in the first
minutes of reperfusion [21]; yet, the underlying mecha-
nisms remain to be characterized with regard to the
response to injury and cardioprotection in the aging heart,
representing a highly relevant topic considering our aging
population.
Finally, translating a therapeutic cardioprotective
approach that targets mitochondria into the patients´ benefit
has recently been illustrated with the neutral results of the
CIRCUS trial: This trial failed to demonstrate improved
clinical outcomes at 1 year (endpoints: cardiac death, heart
failure, and adverse left ventricular remodeling) in STEMI
patients who received an intravenous bolus of the MPTP
inhibitor cyclosporine-A prior to PPCI [14]. Although the
reasons for the failure of this trial are not clear, a number of
factors should be taken into consideration: (1) Not all
experimental studies investigating the infarct-limiting
effects of CsA have been positive [44, 60], and the clinical
data supporting its cardioprotective effects in STEMI
patients have been limited; (2) In the CIRCUS trial, a novel
formulation of cyclosporine called CicloMulsion was used,
whereas Sandimmune was used in the original study [79]—
the intralipid carrier vehicle used in CicloMulsion has been
reported in experimental studies to be cardioprotective
[53], and therefore its presence may have diminished a
difference between CsA and vehicle control; (3) Although
the initial positive proof-of-concept study only recruited
patients treated by direct stenting to ensuring abrupt
reperfusion without any angioplasty pre-dilatation [79], the
CIRCUS trial also recruited STEMI patients who had not
been directly stented [14, 32, 34].
Combination therapy as a cardioprotective
strategy
While several single-target treatment strategies failed to
improve clinical outcomes in patients with ischemic heart
disease [29, 33, 52], the concept of combination therapy as
a potentially more effective approach for preventing
myocardial reperfusion injury was introduced by David
Garcia-Dorado (Spain). He has investigated the MI-
limiting effects of combining ischemic postconditioning
with a pharmacological cardioprotective strategy using an
in vivo porcine model of acute IRI [83]. Based on the
cardioprotective effects of glucagon-like peptide-1 (GLP-
1) [30] or its analogs (such as exenatide) [61, 103],
administered at the onset of reperfusion, their combination
with RIC resulted in a significant reduction of infarct size
as compared to the individual treatments alone and
appeared to be mediated through two distinct pro-survival
pathways [4]. In the COMBinAtion Therapy in Myocardial
Infarction (COMBAT-MI) trial (ClinicalTrials.gov Identi-
fier: NCT02404376), STEMI patients treated by PPCI will
be subjected to this combined therapy, aiming to protect
against myocardial infarction and prevent the onset of heart
failure.
High-density lipoprotein and cardiovascular
disease
Low levels of high-density lipoprotein (HDL) cholesterol
constitute a major risk factor for cardiovascular disease;
however, recent therapies aimed at raising HDL levels have
failed—the underlying reasons remain unclear. Native and/
or synthetic HDL-subtypes were studied in experimental
models of IHD to characterize their possible role in car-
dioprotection, and Sandrine Lecour (South Africa) reported
that HDL subtype 3, containing a high level of sphin-
gosine-1 phosphate, may be superior against acute IRI than
HDL subtype 2 [7], indicating that it is the quality of HDL
rather than its overall quantity that confers the cardiovas-
cular benefits [84–86].
The close proximity of epicardial adipose tissue toward
the media of arteries and its colocalization with atheroma
lesions commonly observed in patients submitted to
revascularization strongly suggests an active role of epi-
cardial adipose tissue in the genesis and progression of
atherosclerosis [63]. Epicardial adipose tissue may thereby
act as a paracrine organ in the induction of inflammation
and the regulation of the metabolism of vascular smooth
muscle cells. Based on clinical studies, the contribution of
epicardial adipose tissue and HDL in atheroma calcifica-
tion of coronary arteries was proposed by Oscar Perez-
Mendez (Mexico) [24]. Here, an altered mRNA-expression
of osteopontin, osteonectin, and osteoprotegerin was
observed in epicardial adipose tissue obtained from
patients with coronary artery disease submitted to revas-
cularization surgery as compared to control individuals
who underwent aortic replacement without MI. Since the
expression changes of these three genes were clearly
associated with the indicated HDL subclasses, a potential
role of HDL in the regulation of atheroma calcification
appears likely.
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Inflammation in myocardial infarction
and subsequent left ventricular remodeling
Atherosclerosis is a chronic inflammatory disease and is
one of the major underlying causes of an acute myocardial
infarction [55]. At the meeting, Ju¨rgen Bernhagen (Ger-
many) summarized the wealth of evidence supporting the
pro-atherogenic effects of the chemokine-like cytokine
macrophage migration-inhibitory factor (MIF) and high-
lighted emerging novel data reporting its cardioprotective
activities in the setting of acute myocardial IRI. His pre-
sentation reviewed the distinct mechanistic differences
between MIF’s pro-atherogenic action in the vasculature
(CXCR2/4-mediated leukocyte recruitment, vascular
inflammation, and plaque destabilization) versus its car-
dioprotective action in the ischemic heart (CD74/AMPK-
and S-nitrosylated MIF-mediated cardioprotection). From a
therapeutic perspective, blocking MIF to prevent athero-
genesis may adversely block the cardioprotective effect of
MIF and should be used with caution. His research group
has identified CXCR7 as a novel, fourth, MIF receptor [3,
12]. Finally, further translational considerations were dis-
cussed on the role of the broader MIF protein family in
clinical outcomes of cardiac surgery patients [96]. Fur-
thermore, upon myocardial infarction, cytokines, such as
tumor-necrosis-factor a (TNF-a) as well as alarmins, par-
ticularly extracellular RNA (eRNA) become released or
liberated from the injured cardiac tissue and represent
mediators of acute myocardial IRI [10, 11], as reported by
Klaus T. Preissner (Germany). In fact, patients subjected to
acute global IRI during cardiac bypass surgery and
exhibited significant elevation of plasma eRNA and TNF-a
[9]. In experimental models, including in vivo murine
myocardial IRI or the isolated Langendorff-perfused rat
heart, as well as in cardiomyocytes subjected to hypoxia,
eRNA promoted TNF-a liberation through the activation of
TNF-a converting enzyme (TACE) [10]. Conversely, TNF-
a promoted further eRNA release especially under
hypoxia, thereby feeding a vicious cell damaging cycle
during IRI with the massive production of oxygen radicals,
mitochondrial damage, decrease in antioxidant enzymes,
and decline of cardiomyocyte functions (unpublished data).
The administration of RNase1 or the TACE-inhibitor TAPI
prevented cell death and significantly decreased myocar-
dial infarction. This regimen allowed the reduction in
cytokine release, normalization of antioxidant enzymes as
well as preservation of cardiac tissue. Finally, a dramatic
increase of endogenous vascular RNase1 in human subjects
was achieved by inducing remote ischemic preconditioning
[37], a noninvasive intermittent limb ischemia and
reperfusion using a simple external occluder, thereby
proving the impact of the eRNA/RNase system in remote
ischemic preconditioning [9].
The left ventricular (LV) remodeling, which takes place
following an acute MI, is a critical determinant of final LV
systolic function, the onset of heart failure and adverse
clinical outcome. In this regard, Elisa Liehn (Germany)
discussed the role of immune cells which are able to
modify collagen synthesis [56–58] and to activate different
signaling pathways in myofibroblasts, with consequences
on tissue healing, scar formation, and heart function after
an acute MI [15, 43, 89]. In particular, neutrophils activate
inflammatory- (TGF-ß1, IL-1ß), differentiation-, migra-
tion-, proliferation- and angiogenesis-related genes, thus
maintaining a soft cytoskeletal structure, whereas mono-
cytes activate inflammatory- (angiotensin II, NFjB),
apoptosis- and remodeling-related genes, thereby increas-
ing the stiffness of the fibroblasts. As a consequence, tar-
geting the extracellular matrix to prevent LV remodeling
post-MI appears to be a promising therapeutic approach to
provide synergistic benefits with cardiomyocyte-directed
therapies.
Cardiac myosin binding protein C: a novel
biomarker for myocardial injury
The ability to detect the presence of myocardial necrosis in
patients presenting with chest pain as a criterion for diag-
nosing an acute MI depends on the ability to accurately
quantify the extent of damage to the myocardium [102].
The use of increasingly sensitive assays for the cardiac
forms of Troponin I (cTnI) and Troponin T (cTnT) has
revolutionized the care of patients presenting with sus-
pected non-ST elevation acute coronary syndromes
(NSTE-ACS) [70]. However, troponins are released slowly
after cardiac injury, and it is therefore necessary to take
heed of their exceedingly low concentrations. Conse-
quently, sensitivity is achieved but at the expense of poor
specificity [47]. Following a systematic screen of proteins
that appeared in the coronary sinus after mild myocardial
infarction, Michael Marber (UK) presented the cardiac
restricted Cardiac Myosin Binding Protein C (cMyC) as a
potential new biomarker [41] with faster release and
clearance kinetics than the troponins [6]. The different
dynamics of this novel biomarker would be expected to
translate into improved diagnostic performance for the
detection of acute MI in NSTE-ACS, a hypothesis which is
currently being tested in a large unselected cohort of such
patients [25].
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Cellular adaptation to hypoxia in cardiovascular
disease
Different endogenous adaptive responses to acute IRI in
the heart may mobilize as yet unrecognized pathogenetic
factors and help to identify novel therapeutic targets for
cardioprotection. The hypoxia-inducible factors HIF-1a
and HIF-2a orchestrate the body’s adaptive response to
hypoxia (a major component of IRI) through the tran-
scription and translation of several hundred proteins. While
HIF-1a has been suggested as a therapeutic target for
cardioprotection [35, 77], little is known about cardiac
HIF-2a, which is involved in hypoxic signaling as well.
Julian Aragone´s (Spain) provided new information on the
HIF-2a isoform, which acts as an mTORC1 activator via
the amino acid carrier SLC7A5, especially promoting
growth of renal cell carcinoma [19]. While several exper-
imental studies have investigated the tissue protective role
of HIF-2a in the brain [81], kidney [46], or skeletal muscle
[5], respective studies in the heart have not been carried out
yet. Since ischemia-provoked HIF-2a activation is essen-
tial for the transcription of new proteins that would take
some time, therapeutic approaches appear to applicable
more towards a delayed cardioprotection rather than to
acute protection against IRI.
While hypoxia is known as a stimulus for the increase in
sympathetic tone, observed in patients with arterial hyper-
tension, Nephtali Marina (UK) presented evidence that the
brainstem in hypertensive animals (spontaneously hyperten-
sive rats, SHR) was relatively hypoxic as well, compared to
normotensive Wistar rats [64]. As a consequence, increased
levels of ‘‘ambient’’ ATP and lactate in the brainstem of SHR
contributed to the development of arterial hypertension by
increasing the activity of the pre-sympathetic circuits. Fur-
thermore, it was shown that facilitated breakdown of extra-
cellular ATP-modulated sympathetic activity [65] and
attenuated the development of hypertension in SHR [64]. The
importance of the Cushing reflex mechanism in the mainte-
nance of adequate oxygen delivery to vital centers of the brain
and its role in the pathogenesis of arterial hypertension was
indicated as well, demonstrating the importance of glial cells
in the regulation of sympathetic activity. Future studies are
needed to clarify the metabolic and vascular mechanisms
leading to the development of brainstem hypoxia in human
subjects with arterial hypertension.
Macrophage polarization as an anti-inflammatory
therapeutic strategy
A variety of inflammatory processes has been shown to
initiate and/or sustain molecular processes culminating in
CVD [55, 80]. As such, the different steps of the
inflammatory cascade as principal mechanism of innate
immunity, of host defence and of tissue regeneration may
persist or becomes dysregulated, resulting in chronic
inflammatory disorders of the cardiovascular system, such
a atherosclerosis [69]. In this regard, mono-
cytes/macrophages respond to external stimuli with rapid
changes in the expression of numerous inflammation-re-
lated genes to undergo polarization towards the M1 (pro-
inflammatory), M2 (anti-inflammatory), or related sub-
phenotypes [8, 13, 62]. Despite the absence of chitin, a
polymer of b-N-acetyl-glucosamine in mammals [45], the
chitin-cleaving glycosyl hydrolase chitotriosidase (Chiti-
nase 1, CHIT1) is abundantly produced and secreted by
activated macrophages in association with various human
diseases. Importantly, elevated chitinase activity has been
found in atherosclerotic lesions [50], and William Boisvert
(USA) presented data that indicate a beneficial role for
chitinase against vessel degeneration. In particular, the
chitinase inhibitor allosamidin was shown to polarize
macrophages towards the M1 phenotype to promote
inflammation, indicative for the fact that chitinase may
play a protective role in the pathogenesis of atherosclerosis
by keeping macrophages in the M2 phenotype and pro-
moting lipid uptake and efflux. Further investigations need
to clarify the underlying protective mechanisms of chiti-
nase and its possible use as a natural anti-atherogenic drug.
It has been recently shown that eRNA can exert pro-
thrombotic and pro-inflammatory properties in the cardio-
vascular system and provoke cytokine mobilization as well
as macrophage polarization, independent of Toll-like
receptor-3 activation [91, 92]. Hector A. Cabrera-Fuentes
(Germany and Singapore) demonstrated that mouse bone
marrow-derived-macrophages (BMDM), which were dif-
ferentiated with mouse macrophage-colony-stimulating
factor into the M2-phenotype, were found to be skewed
toward the inflammatory M1-phenotype when exposed to
eRNA [8]. In accordance with the proposed actions of
eRNA as a pro-inflammatory ‘‘alarm signal’’ and triggering
factor for TACE, these data may shed light on the role of
eRNA in the context of chronic inflammatory diseases such
as atherosclerosis.
The bi-functional ‘‘Transient receptor potential melas-
tatin-2’’ (TRPM2), which combines a nonselective calcium
(Ca2?)-permeable channel with an adenosine diphosphate
ribose pyrohydrolase activity [97], is activated by intra-
cellular adenosine diphosphate ribose and allows both
Ca2? influx into the cell and/or Ca2? release from lyso-
somes, contributing to cell migration, cell death, cytokine
production, as well as degranulation in monocytes, den-
dritic cells, neutrophils, and mast cells [51, 73, 97, 98].
Adriana Sumoza-Toledo (Mexico) presented information
on cardiac TRPM2, which is involved in inflammatory
processes caused by oxidative stress, indicative for a role of
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this channel protein in protection against cardiac IRI [68]
as well as for the maintenance of cardiac myocyte bioen-
ergetics [39]. Thus, TRPM2 may also provide a potential
target to regulate hyper-inflammatory processes in CVD.
Targeting endothelial permeability as an
anti-inflammatory therapeutic strategy
Endothelial junctional dynamics plays an important role
not only in regulating endothelial permeability for a variety
of solutes but also in controlling unwanted leukocyte
emigration into tissues. A close interaction between the
vascular endothelial (VE) -cadherin/catenin complex, the
structural and functional backbone of endothelial cell
junctions, and actin filament dynamics including actin
polymerization and actin/myosin-mediated contractility,
simultaneously maintains integrity and dynamics. Due to
the lifelong shear stress-dependent biomechanical forces at
specific sites of the vascular tree, the affected endothelial
cells become continuously stimulated and acquire a dys-
functional phenotype that resembles the inflammatory
endothelium. Such chronic conditions are associated with
the disturbance of the vascular barrier properties and allow
uncontrolled adhesion and transmigration of pro-inflam-
matory cells into the neointimal region of the inflammatory
vessel wall to feed the atherogenic process. To follow the
time-related changes and molecular arrangements of
endothelial cell junction dynamics, life cell imaging using
fluorescent tagged proteins has been very instrumental, as
addressed by Hans Schnittler (Mu¨nster, Germany). Here,
the formation of ‘‘Junction associated intermittent lamel-
lipodia’’ (JAIL) has recently been reported to be one of the
key mechanisms that control junction remodeling by lar-
gely maintaining cell-junction integrity [1, 2, 88]. JAIL are
actin-driven and ARP2/3-N-WASP-controlled small
plasma membrane protrusions appearing at gaps between
VE-cadherin clusters, such that JAIL form new VE-cad-
herin adhesion plaques that cluster during JAIL retraction
and subsequently become incorporated into the junctions.
This process constitutively remodels VE-cadherin patterns
and maintains endothelial integrity at the same time. This
mechanisms also provides the driving force for cellular
motility within a cell monolayer. In response to thrombin
as a temporary pro-inflammatory factor, JAIL inhibition
occurs with subsequent opening of endothelial cell junc-
tions [90]. Although JAIL has been demonstrated to play a
role in angiogenesis and involves the focal contact protein
parvin [23], little is known about the relevance of such
vascular cell connections in the cardiac macro- or micro-
circulation both under healthy conditions or in situations of
IHD. It remains to be tested whether the identification of
distorted cardiac JAIL may serve as marker of
dysfunctional vascular endothelium and/or provide new
targets for protective interventions.
MicroRNAs, platelet dysfunction, and systems
biology approach in cardiovascular research
Platelets from patients with diabetes are hyper-reactive and
demonstrate increased adhesiveness, aggregation, degran-
ulation, and thrombus formation as well as conjugate for-
mation with leukocytes: processes that contribute to the
accelerated development of vascular disease. Part of the
problem seems to be dysregulated platelet Ca2? signaling
and the activation of intra-platelet calpains, which consti-
tute Ca2?-activated proteases that are required for the
limited proteolysis of several substrate proteins and sub-
sequent alterations in platelet signaling. Ingrid Fleming
(Germany) has found that the activation of l- and m-cal-
pain in patients with type 2 diabetes has profound effects
on the platelet proteome and identified septin-5, the inte-
grin-linked kinase (ILK) and Dicer as novel calpain sub-
strates [18, 82]. The calpain-dependent cleavage of septin-
5 disturbed its association with syntaxin-4 and promoted
the secretion of a-granule contents, including TGF-b and
the chemokine CCL5. The cleavage of Dicer in platelets
from diabetic mice or patients thereby reduced the levels of
platelet microRNAs miR-142, miR-143, miR-155, and
miR-223. Deletion of miR-223 in mice resulted in mod-
estly enhanced platelet aggregation, the formation of large
thrombi, and delayed clot retraction compared to wild-type
littermates. A similar dysregulation was detected in plate-
lets from diabetic patients. Proteomic analysis of platelets
from miR-223 knockout mice revealed increased levels of
several proteins including kindlin-3 and coagulation factor
XIII-A: While kindlin-3 was indirectly regulated by miR-
223, factor XIII was a direct target and both proteins were
also altered in diabetic platelets. Most importantly, treating
diabetic mice with a calpain inhibitor for only 12 days
prevented the loss of platelet Dicer as well as the diabetes-
induced decrease in platelet microRNAs and normalized
the platelet proteome as well as platelet function. Whether
or not the activation of calpain and the subsequent cleavage
of Dicer can account for changes in the microRNA profile
associated with other diseases remains to be determined.
Finally, Manuel Mayr (UK) provided an overview from
a systems biology perspective to help integrate the diverse
topics in cardiovascular research for combined technolog-
ical approaches in finding e.g., new biomarkers or causa-
tive relations. This can be achieved using proteomics in
combination with other postgenomics technologies, such as
lipidomics or microRNA profiling as well the integration of
biological information in disease-specific networks for
CVD. Unlike genomics, postgenomics approaches are not
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‘‘off-the-shelf technologies’’ to identify novel biomarker
candidates. Rather than evaluating individual biomarkers
by routine clinical measurements, the linkage of cutting-
edge postgenomics technologies with population studies
aims to explore biomarker panels derived from a multi-
omics approach (proteomics, lipidomics, and microRNA-
omics) in a primary preventive setting [66, 95, 105, 106,
108, 110]. This integration of emerging technologies has
the potential to improve our understanding of the etiology,
prediction and stratification of CVD. As an primary
example, this approach revealed the loss of platelet-related
microRNAs in type 2 diabetes and could link a subset of
platelet microRNAs (miR-126, miR-223, and miR-197) to
cardiovascular risk in the prospective Bruneck study [108–
110]. Consequently, such bioinformatic information may
thus define new pathways where the unraveled molecular
connections may be proven by in vitro experiments, by
preclinical models as well as in clinical trials.
Summary and conclusions
In summary, recent advances in cardiovascular research
were discussed at this New Frontiers in Cardiovascular
Research meeting covering a range of topics including
cardioprotection, inflammation research, and vascular
biology. A number of novel therapeutic targets for medi-
ating cardiovascular protection in relation to a number of
conditions including acute ischemia/reperfusion, heart
failure, and atherosclerosis were introduced at the meeting.
The important issue of translating new therapeutic strate-
gies from the benchside to the bedside was highlighted
given the challenges facing this process—these will have to
be improved should we wish to impact on clinical out-
comes in our patients with CVD.
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